CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors

Launched by ZHEJIANG UNIVERSITY · Apr 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called UCLH801 cells, a type of CAR-T cell therapy, that targets a specific protein (CDH17) found in certain advanced cancers, including biliary tract cancer, colorectal cancer, gastric cancer, and pancreatic cancer. The main goal of the trial is to see how safe and tolerable this therapy is for patients with these types of tumors that have not responded to other treatments. Researchers will also look at how well the therapy works, how the body processes the treatment, and whether there’s any immune reaction to it.

To be eligible for this trial, participants should have a confirmed diagnosis of a solid tumor that is CDH17-positive and have already tried standard treatments without success. They should also be generally healthy enough to tolerate the therapy. Patients can expect to receive an infusion of the UCLH801 cells and will be monitored for any side effects or changes in their condition. This trial is currently recruiting patients aged 18 and older, and those who decide to participate will need to provide informed consent and follow specific guidelines during the study. If you or a loved one are interested, it’s a good idea to discuss this option with your healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histopathologically confirmed malignant solid tumors, including but not limited to colorectal cancer, gastric cancer, pancreatic cancer, and biliary tract tumors.
• • Patients must have failed standard treatments, be intolerant to standard treatments, or lack effective treatment options.
• • At least one measurable lesion as defined by RECIST v1.1 criteria.
• • Tumor tissue must be available either from prior tumor biopsy or by providing new tumor specimens.
• • Tumor specimens must be confirmed as CDH17-positive by immunohistochemistry (IHC) or immunocytochemistry (ICC) staining.
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• • Expected survival time ≥ 3 months.
• • Appropriate organ function: hematological: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Absolute lymphocyte count (ALC) ≥ 0.5 × 10⁹/L. Hemoglobin (HGB) ≥ 80 g/L; Platelet count (PLT) ≥ 75 × 10⁹/L. Liver Function: aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3.0 × ULN (≤ 5.0 × ULN for patients with primary liver tumors or liver metastases); total bilirubin ≤ 1.5 × ULN (≤ 3.0 × ULN for patients with primary liver tumors or liver metastases; ≤ 3 × ULN for Gilbert's syndrome with direct bilirubin ≤ 1.5 × ULN). Coagulation: international normalized ratio (INR) ≤ 1.5 × ULN (unless on therapeutic anticoagulants); activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (unless on therapeutic anticoagulants). Renal Function: serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance rate ≥ 60 mL/min (based on Cockcroft-Gault formula). Cardiac Function: left ventricular ejection fraction (LVEF) ≥ 50% (confirmed by echocardiography). Pulmonary Function: resting oxygen saturation (SpO₂) \> 92% without supplemental oxygen.
• • Female participants of childbearing potential must have a negative pregnancy test.
• • Female participants of childbearing potential or male participants with partners of childbearing potential must agree to use effective contraception during the study and for 1 year after the final cell infusion.
• • Willingness to sign the informed consent form, demonstrating understanding of the study and agreement to comply with study procedures.
• Exclusion Criteria:
• • Women who are pregnant or breastfeeding.
• • Positive hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) with peripheral HBV DNA levels above the lower limit of detection.
• • Positive hepatitis C virus (HCV) antibody with peripheral HCV RNA levels above the lower limit of detection.
• • Positive HIV antibody.
• • Positive syphilis-specific and non-specific antibody tests.
• • Non-hematological toxicity from prior treatment (surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) has not resolved to ≤ CTCAE grade 1 (except for hair loss and peripheral sensory neuropathy).
• • Prior allogeneic tissue or organ transplant (including bone marrow, stem cell, liver, kidney, etc.), except for transplants not requiring immunosuppression (e.g., corneal or hair transplantation).
• • Patients who have previously received CDH17 CAR-T therapy, except those who received CAR-T infusion within this study.
• • Underwent major surgery within 4 weeks prior to signing informed consent and has not fully recovered, or has a history of serious unresolved trauma.
• • Known central nervous system (CNS) metastases (with exceptions for asymptomatic brain metastases or stable clinical symptoms).
• • Severe active infections or pulmonary diseases requiring systemic corticosteroid treatment within 6 months prior to signing informed consent.
• • Symptomatic congestive heart failure (NYHA class II-IV), severe aortic stenosis, or symptomatic mitral stenosis.
• • ECG showing QTc \> 450 ms or QTc \> 480 ms with bundle branch block.
• • Uncontrolled hypertension (SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg).
• • Cerebrovascular accidents within 6 months prior to signing informed consent.
• • Active, chronic, or recurrent severe autoimmune diseases requiring immunosuppressive treatment (with exceptions).
• • Any form of primary or secondary immunodeficiency.
• • Risk of organ perforation or bleeding as judged by the investigator.
• • Severe systemic hypersensitivity reactions to study drugs/components. - Received live attenuated vaccines within 4 weeks prior to signing informed consent.
• • Participated in another clinical study within 4 weeks prior to signing informed consent.
• • History of another malignancy within the past 5 years, except for adequately treated non-melanoma skin cancer or in situ cancers.
• • Diagnosed with neuropsychiatric disorders or any condition deemed by the investigator as unsuitable for participation.